Further research is expanding the role of TNFα inhibition as a therapy, as it has been shown that selectively ablating TNFα receptors can attenuate dopaminergic neurotoxicity, a major neural consequence believed to underlie the development of Parkinson's disease [58], [59]. The gene discussed is TNF; the disease is Parkinson disease.